ORIC-114

ORIC Pharmaceuticals · Phase 1 active Small molecule

At a glance

Generic name	ORIC-114
Sponsor	ORIC Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (PHASE1, PHASE2)
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC (PHASE1)
Effect of Food on the Pharmacokinetics of ORIC-114 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ORIC-114 CI brief — competitive landscape report
ORIC-114 updates RSS · CI watch RSS
ORIC Pharmaceuticals portfolio CI